Comparison between Management and Pharmacotherapy of COVID-19 in Iran and Switzerland

On 30 January 2020, the WHO declared the outbreak of SARS-CoV-2 as a public health emergency. In the present study, we compared the preventative and therapeutic strategies and the success rates of Iran and Switzerland during the COVID-19 outbreak.Materialsand

This study was conducted using electronic databases such as PubMed, Scopus, and Web of Science. In addition, the official documents of developed countries and WHO from 1st February until 15th May 2020 were studied. Relevant documents were reviewed in detail, and vital data were extracted.

Both countries have restriction policies to reduce the infection rate in the prevention setting. These policies, such as the recommendation to all citizens to stay home unless necessary, army participation, and non-face-to-face counseling, were surveyed by similar techniques in both countries. Some policies were implemented in both countries with different protocols. These policies, including social distancing practices, smart distancing methods, business activities, border closures, border controls, and restrictions, travel restrictions, testing and screening for infection and fever, and decreased working hours, were performed in both countries. In the treatment setting, the therapeutic strategy used in Iran consisted of hydroxychloroquine or chloroquine phosphate and anti-viral drugs. Switzerland followed the guidelines of the European countries. The infection rate, recovery rate, and death rate were 0.139%, 78.73%, and 5.91% in Iran, while these rates were 0.352%, 88.81%, and 6.15% in Switzerland, respectively.

Due to the lack of special treatment for the disease, prevention must be considered the most important factor in policymaking. Importantly, observing social distance is the most effective method among the preventative strategies. The capacity of the health care systems to provide optimal services and facilities is an important factor for patients ‘recovery